Mechanism of Action of Aspirin
- Biological Target Cyclooxygenase-1 and Cyclooxygenase-2 (COX-1 / COX-2 (PTGS1/PTGS2))
- Drug Class Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Physiological System Systemic & Hematologic System
- Molecular Modality Small molecule
How Aspirin Works
Aspirin (acetylsalicylic acid) irreversibly inhibits cyclooxygenase (COX), particularly COX-1 in platelets. This lowers the production of thromboxane A₂ (TXA₂), a signaling molecule that promotes platelet activation and aggregation. As a result, aspirin reduces the ability of platelets to form blood clots.
What is cyclooxygenase?
Cyclooxygenase (COX) is an enzyme that converts arachidonic acid into prostaglandin G₂ (PGG₂) and then prostaglandin H₂ (PGH₂). These reactions are the first steps in the production of several important prostanoids, including prostaglandins, prostacyclin (PGI₂), and thromboxanes.
Arachidonic acid is stored within the phospholipids of cell membranes. When a cell is activated or injured, phospholipase A₂ releases arachidonic acid from the membrane. COX then uses arachidonic acid as its substrate.
The COX enzyme contains a long, hydrophobic channel leading to its catalytic site. Arachidonic acid enters this channel and is positioned so that the cyclooxygenase reaction can occur.
Most traditional NSAIDs inhibit COX by binding within this channel and preventing arachidonic acid from reaching the catalytic site.
Aspirin works differently.
COX-1 vs COX-2
There are two major cyclooxygenase isoforms: COX-1 and COX-2. They are closely related enzymes with substantial sequence similarity, but their expression and physiological roles differ.
COX-1 is expressed constitutively in many tissues and contributes to several normal physiological functions. It is important for:
- platelet thromboxane production and platelet aggregation;
- gastric mucosal protection;
- renal blood flow and renal homeostasis;
- production of prostanoids involved in normal vascular and tissue function.
COX-2 is strongly induced in many cells during inflammation by inflammatory mediators, including cytokines such as IL-1 and TNF-α. It therefore contributes substantially to the production of inflammatory prostaglandins.
However, COX-2 is not exclusively an “inflammatory enzyme.” It is also constitutively expressed in certain tissues and contributes to physiological processes, including renal function and vascular prostacyclin production.
The two isoforms therefore should not be thought of simply as “COX-1 = good” and “COX-2 = bad.” Their functions depend on the tissue and physiological context.
How does aspirin inhibit COX?
Aspirin is unusual among NSAIDs because it irreversibly acetylates COX.
Aspirin transfers its acetyl group to a serine residue within the COX active-site channel, Ser530 in human COX-1. This acetylation changes the structure of the channel and prevents arachidonic acid from reaching the catalytic site.
In simple terms:
Aspirin → acetylates COX-1 Ser530 → blocks the COX channel → ↓ conversion of arachidonic acid → ↓ prostanoid synthesis
This is different from most NSAIDs, which bind COX reversibly.
Why is aspirin’s effect on platelets so long-lasting?
The irreversible inhibition of COX-1 is particularly important in platelets.
Platelets have no nucleus and therefore cannot synthesize new COX-1 after the existing enzyme has been irreversibly acetylated. As a result, the platelet remains unable to produce normal amounts of thromboxane A₂ (TXA₂) for the rest of its lifespan.
New platelets produced by the bone marrow eventually restore normal COX-1 activity.
This explains an important pharmacological principle:
Aspirin itself disappears from the blood relatively quickly, but its antiplatelet effect lasts much longer.
COX-1, thromboxane A₂ and platelet aggregation
In platelets, COX-1 converts arachidonic acid into PGH₂, which is then used to produce thromboxane A₂ (TXA₂).
TXA₂ promotes:
- platelet activation;
- platelet aggregation;
- vasoconstriction.
Aspirin reduces TXA₂ production by permanently inhibiting platelet COX-1.
Aspirin → ↓ COX-1 activity → ↓ TXA₂ → ↓ platelet activation and aggregation → ↓ thrombus formation
At the same time, vascular endothelial cells produce prostacyclin (PGI₂), which generally opposes platelet aggregation and promotes vasodilation.
This balance between platelet-derived TXA₂ and vascular PGI₂ is one reason the COX pathway is important in regulating thrombosis and vascular tone.